AKBA vs CYCN

For growth investors, Akebia Therapeutics, Inc.

(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus 3. 7% for Cyclerion Therapeutics, Inc. (CYCN). Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Akebia Therapeutics, Inc.

(AKBA) delivered a total return of -62. 2%, compared to -94. 3% for Cyclerion Therapeutics, Inc. (CYCN). Over 10 years, the gap is even starker: AKBA returned -85. 7% versus CYCN's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cyclerion Therapeutics, Inc.

(CYCN) is the lower-risk stock at 0. 94β versus Akebia Therapeutics, Inc. 's 1. 14β — meaning AKBA is approximately 21% more volatile than CYCN relative to the S&P 500.

By revenue growth (latest reported year), Akebia Therapeutics, Inc.

(AKBA) is pulling ahead at 47. 5% versus 3. 7% for Cyclerion Therapeutics, Inc. (CYCN). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to 9. 9% for Cyclerion Therapeutics, Inc.. Over a 3-year CAGR, CYCN leads at 91. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Akebia Therapeutics, Inc.

(AKBA) is the more profitable company, earning -2. 3% net margin versus -170. 1% for Cyclerion Therapeutics, Inc. — meaning it keeps -2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKBA leads at 9. 9% versus -239. 8% for CYCN. At the gross margin level — before operating expenses — CYCN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cyclerion Therapeutics, Inc.

(CYCN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94)). Both have compounded well over 10 years (CYCN: -98. 7%, AKBA: -85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AKBA is a small-cap high-growth stock; CYCN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.